Call Options on VTYX on 2/13/2023

Ventyx Biosciences, Inc. (VTYX) develops small molecule product candidates to address a range of inflammatory diseases. 

Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.

In addition, the company is developing VTX3232, a CNS-penetrant NLRP3 inhibitor. 

Shares have formed a bullish "cup and handle" formation following company's update on its drug pipeline. We exppect higher share prices for this stock.

We will be trading March 17th Call Options

Last Trade: $42.79

Trading Range: $9.50 to $44.98

Trade Buy 1 March $45.00 Call at $2.00 For a net debit of $2.00 Profit/Loss Analysis Breakeven at $47.00 Maximum profit is unbounded Maximum loss is ($200.00) at strike of $45.00 Closing Summary Sold 1 March $45.00 Call at $0.00

Position closed on 3/17/2023 at price of $0.00 with a -100.00% loss in 32 days.

Updates

3/17/2023 2:54:42 PM

VTYX call options closed

Back to Portfolio